BLUE BELL, PA – September 7, 2010 -- Inovio Pharmaceuticals Corporation (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present a corporate overview at the following investor conferences:
Rodman & Renshaw Annual Global Investment Conference September 13th - 15th, 2010 New York, NY New York Palace Hotel
Presentation: September 13, 2010 2:50 PM ET A live and archived webcast will be accessible on Inovio’s website at www.inovio.com.
Stifel Nicolaus 2010 Healthcare Conference September 15 – 17, 2010 Boston, MA Four Seasons Hotel Presentation: September 15, 2010 2:40 PM ET
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. The company’s SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. When delivered with Inovio’s proprietary electroporation delivery devices the vaccines have been shown to be safe and generate significant immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic), avian flu, and HIV vaccines (both preventive and therapeutic). Inovio is developing its universal influenza vaccines in collaboration with scientists from the University of Pennsylvania and National Microbiology Laboratory of the Public Health Agency of Canada. Other partners and collaborators include Merck, National Cancer Institute, HIV Vaccines Trial Network, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
